FGFR2 and cholangiocarcinoma: While a previously reported US real-world analysis of patients indicated that 95% of patients with an FGFR2 fusion/rearrangement had intrahepatic disease,11 and 98% of patients in FIGHT-202 with FGFR2 fusion had intrahepatic disease,11 participating physicians in our real-world study reported that 70.0% of the patients who received pemigatinib had intrahepatic CCA at initial CCA diagnosis.